Article

The clinical impact of 2 different strategies for initiating therapy in patients with ocular hypertension.

Department of Ophthalmology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Journal of glaucoma (impact factor: 1.74). 01/2011; 20(1):30-6. DOI:10.1097/IJG.0b013e3181d1d20a pp.30-6
Source: PubMed

ABSTRACT To assess the impact of 2 strategies for initiating therapy in ocular hypertension (OH) on drug use, intraocular pressure (IOP), and blindness caused by glaucoma.
Using a simulation model, initiating therapy with timolol (strategy 1) and with latanoprost (strategy 2) was simulated for a hypothetic cohort of ocular hypertension patients with an initial IOP distribution (data of 1000 patients). Adjustment of therapy within 15 months and a subsequent lifelong follow-up, with an IOP dependent conversion to glaucoma, were modeled. The IOP lowering effect of medication (based on a meta-analysis) was applied by Monte Carlo simulation. Therapy could be maintained or changed, depending on the achieved IOP and side effects. Four drugs (latanoprost, timolol, brimonidine, dorzolamide) were used as monotherapy or in combination. Glaucoma conversion rate was based on literature.
Treatment goal was achieved in both strategies in 90% by monotherapy. This was 60% for patients with initial IOP's of 30 mm Hg. The originally prescribed medication was maintained in 66% (1) and in 77% (2). IOP decreased with approximately 34%, from 25.4 mm Hg (mean) to 16.7 mm Hg (1) and to 16.5 mm Hg (2) Blindness per person within 18.7 years of life expectancy was 0.0923 years (1) and 0.0870 years (2), which corresponds to approximately 1 month. The difference between strategies was 2 days spent in blindness per patient.
The difference in clinical effects of the strategies is small. This is largely owing to the key concept of a target pressure, which underlies both strategies.

0 0
 · 
1 Bookmark
 · 
38 Views

Full-text

View
0 Downloads
Available from

Keywords

15 months
 
2 strategies
 
achieved IOP
 
clinical effects
 
Glaucoma conversion rate
 
initial IOP distribution
 
initiating therapy
 
intraocular pressure
 
IOP dependent conversion
 
key concept
 
life expectancy
 
monotherapy
 
Monte Carlo simulation
 
ocular hypertension
 
ocular hypertension patients
 
patients
 
simulation model
 
strategy 1
 
strategy 2
 
subsequent lifelong follow-up
 

Andrea Peeters